The global tissue diagnostics market size was USD 5.07 billion in 2023, calculated at USD 5.41 billion in 2024 and is projected to surpass around USD 10.34 billion by 2034, expanding at a CAGR of 6.7% from 2024 to 2034.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Tissue Diagnostics Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Tissue Diagnostics Market, by Application, 2024-2034
8.1.1 Prostate Cancer
8.1.1.1. Market Revenue and Forecast (2021-2034)
8.1.2. Breast Cancer
8.1.2.1. Market Revenue and Forecast (2021-2034)
8.1.3. Lung Cancer
8.1.3.1. Market Revenue and Forecast (2021-2034)
8.1.4. Gastric Cancer
8.1.4.1. Market Revenue and Forecast (2021-2034)
8.1.5. Other Cancers
8.1.5.1. Market Revenue and Forecast (2021-2034)
9.1. Tissue Diagnostics Market, by Product, 2024-2034
9.1.1. In Situ Hybridization
9.1.1.1. Market Revenue and Forecast (2021-2034)
9.1.2. Immunohistochemistry
9.1.2.1. Market Revenue and Forecast (2021-2034)
9.1.3. Digital Pathology and workflow
9.1.3.1. Market Revenue and Forecast (2021-2034)
9.1.4. Primary and Special Staining
9.1.4.1. Market Revenue and Forecast (2021-2034)
9.1.5. Anatomic Pathology
9.1.5.1. Market Revenue and Forecast (2021-2034)
10.1. Tissue Diagnostics Market, by End-User, 2024-2034
10.1.1. Research Laboratories
10.1.1.1. Market Revenue and Forecast (2021-2034)
10.1.2. Hospitals
10.1.2.1. Market Revenue and Forecast (2021-2034)
10.1.3. Contract Research Organizations (CROs)
10.1.3.1. Market Revenue and Forecast (2021-2034)
10.1.4. Pharmaceutical Organizations
10.1.4.1. Market Revenue and Forecast (2021-2034)
11.1. North America
11.1.1. Market Revenue and Forecast, by Application (2021-2034)
11.1.2. Market Revenue and Forecast, by Product (2021-2034)
11.1.3. Market Revenue and Forecast, by End-User (2021-2034)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Application (2021-2034)
11.1.4.2. Market Revenue and Forecast, by Product (2021-2034)
11.1.4.3. Market Revenue and Forecast, by End-User (2021-2034)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Application (2021-2034)
11.1.5.2. Market Revenue and Forecast, by Product (2021-2034)
11.1.5.3. Market Revenue and Forecast, by End-User (2021-2034)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Application (2021-2034)
11.2.2. Market Revenue and Forecast, by Product (2021-2034)
11.2.3. Market Revenue and Forecast, by End-User (2021-2034)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Application (2021-2034)
11.2.4.2. Market Revenue and Forecast, by Product (2021-2034)
11.2.4.3. Market Revenue and Forecast, by End-User (2021-2034)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Application (2021-2034)
11.2.5.2. Market Revenue and Forecast, by Product (2021-2034)
11.2.5.3. Market Revenue and Forecast, by End-User (2021-2034)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Application (2021-2034)
11.2.6.2. Market Revenue and Forecast, by Product (2021-2034)
11.2.6.3. Market Revenue and Forecast, by End-User (2021-2034)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Application (2021-2034)
11.2.7.2. Market Revenue and Forecast, by Product (2021-2034)
11.2.7.3. Market Revenue and Forecast, by End-User (2021-2034)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Application (2021-2034)
11.3.2. Market Revenue and Forecast, by Product (2021-2034)
11.3.3. Market Revenue and Forecast, by End-User (2021-2034)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Application (2021-2034)
11.3.4.2. Market Revenue and Forecast, by Product (2021-2034)
11.3.4.3. Market Revenue and Forecast, by End-User (2021-2034)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Application (2021-2034)
11.3.5.2. Market Revenue and Forecast, by Product (2021-2034)
11.3.5.3. Market Revenue and Forecast, by End-User (2021-2034)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Application (2021-2034)
11.3.6.2. Market Revenue and Forecast, by Product (2021-2034)
11.3.6.3. Market Revenue and Forecast, by End-User (2021-2034)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Application (2021-2034)
11.3.7.2. Market Revenue and Forecast, by Product (2021-2034)
11.3.7.3. Market Revenue and Forecast, by End-User (2021-2034)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Application (2021-2034)
11.4.2. Market Revenue and Forecast, by Product (2021-2034)
11.4.3. Market Revenue and Forecast, by End-User (2021-2034)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Application (2021-2034)
11.4.4.2. Market Revenue and Forecast, by Product (2021-2034)
11.4.4.3. Market Revenue and Forecast, by End-User (2021-2034)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Application (2021-2034)
11.4.5.2. Market Revenue and Forecast, by Product (2021-2034)
11.4.5.3. Market Revenue and Forecast, by End-User (2021-2034)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Application (2021-2034)
11.4.6.2. Market Revenue and Forecast, by Product (2021-2034)
11.4.6.3. Market Revenue and Forecast, by End-User (2021-2034)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Application (2021-2034)
11.4.7.2. Market Revenue and Forecast, by Product (2021-2034)
11.4.7.3. Market Revenue and Forecast, by End-User (2021-2034)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Application (2021-2034)
11.5.2. Market Revenue and Forecast, by Product (2021-2034)
11.5.3. Market Revenue and Forecast, by End-User (2021-2034)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Application (2021-2034)
11.5.4.2. Market Revenue and Forecast, by Product (2021-2034)
11.5.4.3. Market Revenue and Forecast, by End-User (2021-2034)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Application (2021-2034)
11.5.5.2. Market Revenue and Forecast, by Product (2021-2034)
11.5.5.3. Market Revenue and Forecast, by End-User (2021-2034)
12.1. Abbott Laboratories
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. F. Hoffmann-La Roche Ltd.
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Thermo Fisher Scientific Inc.
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Danaher
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Siemens
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. bioMérieux SA
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. QIAGEN
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. GE Healthcare
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Becton, Dickinson and Company
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Merck KGaA
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
14.1. About Us
14.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample